49 completed, 1 recruiting, 1 terminated, 1 unknown. 47 Phase 1, 3 Phase 3, 2 Not applicable, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 47 | Completed 44, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Not applicable | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Treatment C: new trials by email Literature Review of Treatment C trials Research Report on Treatment C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants Treatment A, Treatment B, Treatment C - Vasomotor Symptoms | Phase 1 | Completed | Bayer | 18 | 2025-11-05 | 2026-01-27 |
| A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers treatment A, treatment B, treatment C - Dyslipidemia | Phase 1 | Recruiting | Korea United Pharm. Inc. | 50 | 2025-08-12 | 2025-09-09 |
| A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Withdrawn | Pfizer | 2025-04-28 | 2025-04-24 | |
| A Study to Assess the Abuse Potential of Intranasal Cebranopadol Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug - Abuse, Drug | Phase 1 | Completed | Tris Pharma, Inc. | 48 | 2024-06-28 | 2025-12-18 |
| Electrophysiological Effects of Potential QT Prolonging Drugs Clarithromycin, Pimozide, Placebo (Part 1) - Drug-induced QT Prolongation, Pharmacokinetics | Phase 1 | Completed | Food and Drug Administration (FDA) | 44 | 2023-03-21 | 2023-06-22 |
| Relative Bioavailability of Evobrutinib Tablet Batches Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 28 | 2023-01-18 | 2025-12-23 |
| Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics Treatment A, Treatment B, Treatment C - Healthy Adult Participants | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 42 | 2022-10-13 | 2025-02-14 |
| A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers Zavegepant 100mg non-enteric coated soft gel capsule, Zavegepant 100mg immediate release tablet, Zavegepant 2 x 100mg immediate release tablets - Biological Availability | Phase 1 | Completed | Pfizer | 52 | 2022-08-24 | 2024-10-01 |
| Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers Treatment A, Treatment B, Treatment C - Healthy Volunteers | Phase 1 | Completed | Novartis Pharmaceuticals | 33 | 2022-02-03 | 2022-12-28 |
| To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Completed | JW Pharmaceutical | 40 | 2022-01-17 | 2022-07-19 |
| Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers Treatment A, Treatment B, Treatment C - Perennial Allergic Rhinitis, Rhinitis, Allergic | Not applicable | Completed | Altamira Medica Ltd. | 37 | 2021-11-10 | 2024-09-19 |
| Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers Treatment A, Treatment B, Treatment C - Heart Failure | Phase 1 | Completed | AstraZeneca | 20 | 2021-06-29 | 2021-09-09 |
| Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS) Crizotinib - Healthy Participants | Phase 1 | Completed | Pfizer | 25 | 2021-04-16 | 2022-01-20 |
| A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol Treatment A, Treatment B, Treatment C - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Completed | AstraZeneca | 47 | 2020-10-19 | 2023-01-23 |
| The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2 Treatment A, Treatment B, Treatment C - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Completed | AJU Pharm Co., Ltd. | 30 | 2020-07-02 | 2021-07-21 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T, CKD-393 0.5/100/1000mg formulation 1 Tab. 1T, CKD-393 0.5/100/1000mg formulation 2 Tab. 1T - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2020-04-08 | 2021-04-30 |
| A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718 Treatment A, Treatment B, Treatment C - Coronary Artery Disease | Phase 1 | Completed | AstraZeneca | 14 | 2019-09-20 | 2019-11-15 |
| Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma Treatment A, Treatment B, Treatment C - Asthma; Eosinophilic | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 810 | 2019-08-28 | 2022-04-08 |
| Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers CKD-330 16/10mg Tab. 1T and D086 Tab. 1T, CKD-333 16/10/40mg formulation 1 Tab. 1T, CKD-333 16/10/40mg formulation 2 Tab. 1T - Hypertension, Dyslipidemias | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2019-07-28 | 2020-01-30 |
| Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants Treatment A, Treatment B, Treatment C - Healthy Volunteers | Phase 1 | Completed | Pfizer | 25 | 2019-06-12 | 2019-11-15 |
Showing 20 of 53. Sign in to see all of them.
Asthma (3) · Diabetes Mellitus, Type 2 (2) · Dyslipidemias (2) · Heart Failure (2) · Hypertension (2) · Pulmonary Disease, Chronic Obstructive (2) · Acute Kidney Injury (1) · Arthritis, Rheumatoid (1) · Coronary Artery Disease (1) · HIV Infections (1) · Hypotension (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Malaria (1) · Migraine Disorders (1) · Neurofibromatosis 1 (1)
AstraZeneca (10) · Pfizer (10) · Chiesi Farmaceutici S.p.A. (2) · Chong Kun Dang Pharmaceutical (2) · International Partnership for Microbicides, Inc. (2) · AJU Pharm Co., Ltd. (1) · Alexion Pharmaceuticals, Inc. (1) · Altamira Medica Ltd. (1) · Alvogen Korea (1) · Bayer (1) · Boehringer Ingelheim (1) · Corcept Therapeutics (1) · Food and Drug Administration (FDA) (1) · Gilead Sciences (1) · INSYS Therapeutics Inc (1)
United States (14) · United Kingdom (8) · Singapore (6) · Germany (5) · South Korea (5) · Canada (3) · Belgium (2) · Bulgaria (1) · France (1) · Mexico (1) · Netherlands (1)
Rainard Fuhr, Dr. med. (2) · Alen Jambrecina (1) · Angela Eakin, MD (1) · Annelize Koch, Dr. (1) · David Han, Dr. (1) · Denis Audet, MD (1) · Don Kellerman, PharmD (1) · Jennifer Boston, MSN, APNP (1)
PMID 41920422, PMID 22535635, PMID 33834354, PMID 34817414, PMID 35170228, PMID 35410754, PMID 37607661, PMID 39498822, PMID 40307580
2018 (2), 2014 (1), 2019 (1)